Skip to content

Lannett to exclusively distribute generic Flovent Diskus in US

August 17, 2020

Lannett Company (NYSE:LCI) inks an agreement with Respirent Pharmaceuticals Co., Ltd. for exclusive U.S. distribution rights to the latter’s generic version of GlaxoSmithKline’s (NYSE:GSK) asthma med Flovent Diskus (Fluticasone Propionate Powder Inhaler).

Per IQVIA, the U.S. market is $94M.

LCI also has exclusive U.S. distribution rights to Repirent’s generic version of GSK’s Advair Diskus (Fluticasone Propionate – Salmeterol Xinafoate Powder Inhaler), the term of which has been extended to 12 years from 10.

https://seekingalpha.com/news/3606102-lannett-to-exclusively-distribute-generic-flovent-diskus-in-u-s

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: